Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Gross Profit (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Gross Profit for 16 consecutive years, with -$59654.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gross Profit rose 88.52% year-over-year to -$59654.0, compared with a TTM value of -$443314.0 through Sep 2025, up 76.72%, and an annual FY2024 reading of -$2.0 million, down 606.42% over the prior year.
  • Gross Profit was -$59654.0 for Q3 2025 at China Pharma Holdings, up from -$87010.0 in the prior quarter.
  • Across five years, Gross Profit topped out at $301936.0 in Q4 2021 and bottomed at -$1.0 million in Q2 2024.
  • Average Gross Profit over 5 years is -$141794.9, with a median of -$137756.0 recorded in 2022.
  • The sharpest move saw Gross Profit tumbled 728.01% in 2021, then skyrocketed 204.99% in 2023.
  • Year by year, Gross Profit stood at $301936.0 in 2021, then tumbled by 85.86% to $42682.0 in 2022, then crashed by 285.46% to -$79158.0 in 2023, then plummeted by 102.87% to -$160589.0 in 2024, then surged by 62.85% to -$59654.0 in 2025.
  • Business Quant data shows Gross Profit for CPHI at -$59654.0 in Q3 2025, -$87010.0 in Q2 2025, and -$136061.0 in Q1 2025.